Core Viewpoint - Rosen Law Firm is reminding investors who purchased BioAge Labs, Inc. stock during its IPO on September 26, 2024, of the March 10, 2025, deadline to become a lead plaintiff in a class action lawsuit related to the company's alleged misleading statements regarding its clinical trials [1]. Group 1: Class Action Details - Investors who purchased BioAge stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm for more information [3][7]. - A class action lawsuit has already been filed, and interested parties must act by March 10, 2025, to serve as lead plaintiff [3]. Group 2: Background of the Case - The lawsuit claims that BioAge misrepresented the safety and efficacy of its lead product candidate, azelaprag, in connection with the STRIDES clinical trial, which was expected to yield topline results in 2025 [5]. - BioAge's collaboration with Eli Lilly's Chorus clinical development organization was highlighted as part of the trial's design and execution [5]. - The IPO suggested no safety concerns, but the company later discontinued the STRIDES Phase 2 study due to elevated liver enzyme levels in subjects, indicating potential organ damage [6]. Group 3: Allegations of Misleading Information - The lawsuit alleges that BioAge failed to disclose the potential for liver transaminitis from previous clinical trials and preclinical studies, making their statements in the registration statement materially misleading at the time of the IPO [6]. - When the true details about the safety concerns became public, investors reportedly suffered damages [6].
BIOA Deadline: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit